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Summary Regionally administered vasopressors might increase tumour chemotherapy uptake by differentially constricting normal and
tumour blood vessels, leading to a selective increase in blood flow to the tumour. In this study, we compared the effects of the vasopressors
angiotensin 11, vasopressin and endothelin and the vasodilator calcitonin gene-related peptide (CGRP) by continuously measuring liver
parenchymal and tumour blood flow during a 30-min regional vasoactive infusion in a rat HSN liver metastasis model. Vasopressin and
angiotensin 11 produced a vasoconstriction that decreased despite continued infusion, while endothelin infusion led to prolonged
vasoconstriction with a more gradual onset. CGRP infusion resulted in increased vessel conductance but a reduction in blood flow due to
systemic hypotension. The tumour to normal flow ratio (TNR) was transiently increased during infusion of all pressors, but only endothelin
produced sufficient change to result in a rise in average TNR throughout pressor infusion. Continuous liver and tumour blood flow
measurement throughout vasoactive infusion demonstrated that the extent and the duration of blood flow change varied with the agents
assessed. No vasoactive agent increased tumour blood flow, but endothelin had the most suitable vasoactive properties for enhancing
tumour uptake of continuously infused chemotherapy.
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Forty per cent of patients with large bowel cancer develop liver
metastases (Allen-Mersh et al, 1991). Most will be treated by
systemic 5-fluorouracil (5-FU)/folinic acid chemotherapy, which
produces complete or partial tumour responses in only 23% of
patients (Advanced Colorectal Cancer Meta-analysis Project,
1993). There is a steep dose-response relationship between fluoro-
uracil concentration and tumour cell kill (Hrynuik et al, 1987), and
one reason for the limited response of liver metastases to
chemotherapy is poor tumour drug penetration. Tumour fluori-
nated pyrimidine levels can be increased tenfold by regional
compared with systemic chemotherapy administration (Ensminger
et al, 1978), resulting in a 40-50% partial response rate (Dworkin
and Allen-Mersh, 1992) and significant survival benefit (Allen-
Mersh et al, 1994). However, attempts to further improve response
by increasing regional chemotherapy dose have produced unac-
ceptable hepatotoxicity (Kemeny et al, 1990) because of a greater
first-pass drug extraction by normal liver parenchyma than by
metastases (Ensminger et al, 1978). Thus, a means of increasing
tumour drug uptake without producing parenchymal toxicity is
required.
As chemotherapy uptake is influenced by blood flow (Dworkin
et al, 1996), one solution may be to increase tumour and reduce
liver parenchymal blood flow by vasoactive manipulation.
Previous studies of this strategy have focused on enhancing the
tumour-liver parenchymal blood flow ratio (TNR) at a single time
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point, with the aim of increasing tumour uptake of a bolus
chemotherapy dose (Sasaki et al, 1985). However, the best results
for treatment of colorectal liver metastases involve prolonged
fluorinated pyrimidine infusion (Dworkin and Allen-Mersh,
1992), which would require continuous vasoactive infusion.
Therefore, continuous blood flow measurement is needed for
assessment ofthe effect ofvasoactive agents used with continuous
chemotherapy infusion. We have used laser Doppler flowmetry
(Almond and Wheatley, 1992) to assess liver and tumour blood
flow changes in response to a continuous 30-min regional infusion
of various vasoactive agents in an animal liver metastasis model.
METHODS
Liver metastasis animal model
The Hooded Sarcoma-N (HSN) tumour has similar in vivo
hypovascular flow characteristics to human colorectal metastases
(Hemmingway et al, 1991). It was originally induced chemically
(Currie and Gage, 1973) and has since been maintained in cell
culture with Dulbecco's modified Eagle medium (Sigma) enriched
with 10% fetal calf serum. HSN cells were trypsinized, resus-
pended in saline at a concentration of 5 x 106 ml-' and stored on
ice before in vivo injection. Adult male Chester Beatty Hooded
CBH/cbi rats (weight 300-375 g) were anaesthetized by inhalation
of a halothane-oxygen mixture, and a lower midline laparotomy
was performed. A mesenteric vein was injected with 1 x 106 HSN
cells using a 21G needle, after which pressure was applied for
1-2 min to prevent bleeding. Care was taken to prevent extravasa-
tion of the HSN cells, which may lead to growth of mesenteric
tumour at the injection site. Tumours 4-10 mm in diameter, which
developed within 21-27 days ofinjection, were studied.
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Figure 1 Trace of laser Doppler measurements at a time constant of 0.1 s
and a rate of 20 Hz showing excursions due to pulsatile flow and respiratory
artifact, which were minimized by careful probe placement
Laser Doppler flow measurement
Laser Doppler measurements have previously been investigated
both in vivo and in phantom models and found to be a sensitive
indicator of changes in liver parenchymal and tumour blood
flow (Ackerman et al, 1988; Arvidsson et al, 1988). Blood flow
was measured using the Moor Instruments MBF3D laser
Doppler blood flow monitor. This is a dual-channel source
allowing two probes to be operated simultaneously. The solid-
state laser has a wavelength of780-820 nm and a 15 kHz band-
width. Laser light illuminates the tissue over an estimated 1-mm
radius from the probe tip (Acker et al, 1990). The light is scat-
tered and undergoes a frequency shift in proportion to red cell
concentration and speed. This frequency shift is then converted
to a flux value and recorded on the MBF3D monitor in arbitrary
flux units. The upper surface of the liver was most suitable for
placement of the laser Doppler probe, and a single tumour and
an area of normal parenchyma in this position were studied in
each animal. Areas of tumour with overlying liver parenchyma
were excluded. A lightweight metal probe holder supported by
three struts was used to hold each probe in position. Two probes
(each 30 mm in length x 1 mm in diameter) were placed within
a holder and lightly applied to the surface of the liver above an
area of either normal liver or tumour. The optical leads for each
probe were supported above the animal in a metal clamp that
allowed the probe to sit on the tissue surface while minimizing
the weight on the liver but allowing unimpeded liver movement
with respiration. The probe was carefully placed using a 0.1-s
time constant, with readings taken at a frequency of 20 Hz to
minimize artefactal movements, including respiratory excursion
(Figure 1). After the probes had been satisfactorily positioned,
readings were made at a slower frequency of 0.25 Hz using a
3.0-s time constant to provide a smooth measurable trace
(Figures 2 and 3). Before the commencement of the laser
Doppler readings, blood lost during cannulation was replaced
with 1 ml of 0.9% sodium chloride at 37°C, and the abdominal
contents were moistened with saline and protected with cling
film to minimize evaporative loss.
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Figure 2 A single study, involving a 3-s time constant at 4 Hz, showing the
effect ofvasopressin infusion via the gastroduodenal artery (GDA) on liver
and tumour perfusion, blood pressure and TNR. The damping of the artifact
produced by altered laser Doppler characteristics (compare with Figure 1)
and the escape from vasopressin-induced vasoconstriction can be seen
Blood pressure monitoring
A polythene cannula (Portex, 0.4 x 0.8 mm) was inserted into
the right carotid artery and the intra-arterial blood pressure was
measured continuously using a commercial pressure transducer
(Fumess; FC0l 1). Theresults wererecorded on apersonal computer
using Metrabyte (DAS8-PG) signal-processing hardware.
Vasoactive agents and doses
The selection ofvasoactive dose was based on pilot studies whose
aim was to achieve a measurable blood flow change while keeping
the mean systemic blood pressure to within 0.75-1.25 ofbaseline.
The vasoactive agents assessed and the doses administered were:
the vasoconstrictors vasopressin (0.5 gg min-'), angiotensin II
(4 gg kg-' min-') and endothelin I (0.05 gg min-') and the
vasodilator calcitonin gene-related peptide (CGRP) (0.5 ,ig min-').
Experimental procedure
Three to four weeks after mesenteric vein tumour cell injection,
animals were reanaesthetized and an upper midline laparotomy
was performed. A fine haemostat was placed on the lower aspect
of the first part ofthe duodenum, which was retracted downwards
to expose the lesser omentum. The gastroduodenal artery, which
leads into the common hepatic artery, was dissected free with
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Figure 3 A single study of the effect of endothelin infu
gastroduodenal artery (GDA) on liver and tumour perfusi(
conductance, blood pressure and TNR. The onset of vas(
slower but of greater duration than with the other pressor
microvascular forceps using bipolar diathermy
This was then cannulated using polythene
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Figure 4 Typical laser Doppler trace showing the baseline and infusion time
periods during which perfusion values were averaged, and the perfusion (flux)
measurements from which maximal and end perfusion values were derived
Doppler reading taken at the flux point at which there was the
greatest change from baseline (Figure 4) and the end value as the
average flux reading during the last minute of the infusion period
-r'-'-r-' (Figure 4). When percentage values are given, these are the average
60 75 percentage flux change during vasoactive infusion from the average
flux value over the baseline period. The tumour to normal blood
flow ratio is the quotient of tumour by liver parenchymal flux
sion via the within aparticular animal and was calculated by division oftumour
on, liver and tumour flux by liver flux at each time point. The paired Student's t-test was
oconstriction was used throughout to compare differences between baseline and ,s (see Figure 2)
comparable variables after vasoactive infusion.
for haemostasis. RESULTS
tubing (Portex, The numbers of animals in each vasoactive agent infusion group
rating microscope. were: vasopressin, 7; angiotensinII, 8; endothelin I, 8; andCGRP, 9.
ligatures, and the The effects of vasoactive infusion on mean blood pressure are
der to ensure that shown in Table 1 and on liver parenchymal and tumour flux in
ulous haemostasis Figures 2, 3 and 5. It can be seen (Figure 5) that 'all the agents
liver parenchymal tested significantly reduced both average and maximal liver
)plied to the liver parenchymal flux but that this significant reduction only persisted
,ssure monitoring to the end ofendothelin I infusion. Although all pressor agents also
as recorded at the significantly reduced tumour flux throughout the infusion period,
,oactive agent was the tumour-normal ratio (TNR) of maximum flux change was
ery were adminis- significantly increased by all vasopressor agents. However, the
er which the infu- TNR of average flux change was significantly increased only by
mal was killed by endothelin I infusion, and no agent significantly increased TNR of
logical zero, read- flux change at the end ofinfusion.
Doppler probes.
readings for that DISCUSSION
ro.
Liver parenchymal and tumour blood flow changes varied in both
extent and duration with the vasoactive agents assessed in our
study. Angiotensin II and vasopressin produced arapid fall in liver
ymal blood flows parenchymal blood flow that was not sustained beyond 15 min
ogical zero from despite continued vasoconstrictor infusion (Figures 2 and 5). Loss
or infusion period of vasoconstriction during continuous angiotensin infusion has
ined as the laser been observed previously in canine forelimb experimental studies
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Table 1 The increase in mean blood pressure (BP) when vasopressor
agents were infused and the decrease when the dilator CGRP was infused
Vasoactive agent Baseline mean BP Maximum change in mean
Mean mmHg (s.d.) BP during infusion
Mean mmHg (s.d.)
Vasopressin 78 (8) + 26 (7)
Angiotensin II 84 (6) + 18 (11)
Endothelin 83 (12) + 10 (8)
CGRP 82 (6) - 24 (5)
(Grega and Adamski, 1987), and clinical studies have reported
a diminution of vasopressin-induced vasoconstriction during
prolonged continuous regional infusion to control upper gastro-
intestinal haemorrhage (Conn, 1973). We have suggested
(Dworkin et al, 1995) that loss of vasopressin-induced vasocon-
striction may be related to local nitric oxide release, as it can be
prevented or reversed by the nitric oxide inhibitor L-nitro-arginine
methyl ester. Endothelin-induced vasoconstriction was of slower
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onset and longer duration (Figures 3 and 5) than with angiotensin
II or vasopressin. This is in keeping with previous studies
(Withrington et al, 1989) ofthe effect ofendothelin in the liverand
suggests that endothelin-induced vasoconstriction is differently
mediated to that ofangiotensin II or vasopressin.
In order to increase tumour blood flow by vasoactive admin-
istration, there should be a differential response by normal and
tumour circulations to the administered agent. This differential
response could arise from a lack of smooth muscle (Krylova,
1969) or nerves (Mattson et al, 1977) within intratumoral
vessels. Failure of intratumoral vasoconstriction to an infused
vasoconstricting agent might thus lead to preferential blood
flow through the tumour as the resistance in adjacent normal
vessels rises. Neither the vasopressors nor the dilator (CGRP)
that we studied increased intratumoral blood flow. The pressors
induced a similar but less marked pressor effect of the same
duration in tumour compared with normal liver parenchyma
(Figure 5). Some previous studies have suggested an increase
in absolute tumour blood flow (Ackerman et al, 1988;
Hemmingway et al, 1992), while others (Mattsson and Peterson,
1988) have concluded that the tumour circulation reacts to
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Figure 5 The effect of the vasoactive agents tested, for the average (0), maximal (A), and end values (-) as a percentage change from the baseline period,
on liver and tumour blood flow and the tumour-normal blood flow ratio (TNR). *P < 0.05, **P< 0.01, ***P< 0.001 (mean, s.d., paired t-test)
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vasoactive agents in the same way as normal circulation.
Possible explanations for our findings are that the pressor effect
on normal parenchymal vessels supplying the tumour was suffi-
cient to reduce tumour flow or that some intratumoral vessels
were normal vessels that had been surrounded by local tumour
growth but had retained nerves and smooth muscle capable of a
pressor response.
Decreased tumour blood flow could be associated with a
chemotherapy advantage if the TNR was increased, thereby
allowing administration of a higher chemotherapy dose with less
blood flow and drug toxicity to normal tissues. TNR increase has
been shown to enhance the tumour uptake of small tracer mole-
cules (Hemmingway et al, 1991) and the cytotoxic effect (Suzuki
et al, 1981; Bloom et al, 1987). However, previous studies
suggesting that vasoactive agents increase the TNR have measured
blood flow with intermittent measuring techniques; these did not
reveal either blood flow variations throughout vasoactive infusion
(Burton, 1987; Carter et al, 1992) or the extent and direction of
hepatic parenchymal and tumour blood flow change (Hafstrom et
al, 1980; Burton et al, 1985). All the pressors tested in our study
(but not the dilator CGRP) produced a significant maximal
increase in the TNR because of a relatively larger pressor effect in
liver parenchyma than in tumour (Figure 5).
We have previously suggested (Dworkin et al, 1996) that a
significant but transient angiotensin Il-induced TNR increase
achieved less chemotherapy advantage during continuous
regional fluorouracil infusion than would be predicted by a TNR
increase sustained throughout fluorouracil infusion. Assessment
of the effects of continuous vasopressor infusion on both
tumour-normal blood flow ratio and normal tissue blood flow
over the days to weeks involved in clinical regional infusion
chemotherapy would be difficult with the methods used in
this study. However, the continuous flux measurements over a
30-min vasoactive infusion period in the present study did reveal
that, although endothelin I produced the most sustained pressor
effect with the only significant increase in average TNR of the
agents tested (Figure 5), this TNR effect was not sustained
throughout the 30-min infusion (Figures 3 and 5). In addition,
although the maximal effect in our study was to double the TNR,
the average effect over the infusion period was less (roughly a
30% increase). While a regional endothelin-induced increase in
tumour fluorouracil uptake of this order might increase response
(Hrynuik et al, 1987), it might also be limited by the hyperten-
sive or cardiac effects ofendothelin infusion. Although a clinical
study would be needed to determine whether such an approach
offered a therapeutic advantage at endothelin dose levels that did
not damage normal tissues, the results from the present animal
model study suggest that increases in tumour chemotherapy
uptake sufficient to have an important impact on tumour
response or survival are unlikely to be achieved. One reason for
the limited effect of vasoactive blood flow manipulation on
tumour blood flow and chemotherapy uptake may be the absence
of vessels within the tumour for blood to be selectively shunted
into (Burke et al, 1994).
We conclude that the blood flow response to vasoactive infusion
in this model of colorectal liver metastases varied with the agent
tested. Although no agent increased tumour blood flow, maximal
tumour to liver blood flow ratios were increased by vasoconstric-
tors. Only endothelin I produced a significant average TNR
increase, but no agent significantly increased TNR throughout
infusion.
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